Compare Altria Group Inc (MO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs TG Therapeutics Inc — how do they compare? Altria Group Inc trades at $73.25 (market cap $124.67B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Altria Group Inc is far larger — about 15.1× TG Therapeutics Inc's market cap, and Altria Group Inc pays a 5.68% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MO | TGTX | |
|---|---|---|
Market Cap | $124.67B | $8.26B |
Sector | Consumer Staples | Health |
52-Week High | $74.66 | $59.06 |
52-Week Low | $54.72 | $26.39 |
Enterprise Value | $145.75B | $8.50B |
Dividend Yield | 5.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
